Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of Myozyme in late-onset Pompe disease after protocol AGLU02704
2006-003644-31Phase 4Completed
- Sponsor
- Sanofi
- Start
- Dec 2006
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of alglucosidase alfa in Pompe disease, sponsored by Sanofi. Primary endpoints: Long-term safety of Myozyme and Long-term efficacy of Myozyme. Started Dec 2006; status: completed.
02
Drugs
alglucosidase alfa
03
Conditions
Pompe disease
Beyond the preview
Go deeper on 2006-003644-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003644-31.